aibioCSBR Champions Oncology, Inc.
Champions Oncology (CSBR) news
Top story · Oct 16, 2026 · SEC filing 8-K
Champions Oncology reports shareholder vote results
The seven director nominees named in the Company's 2026 proxy statement were elected to serve for a one-year term expiring at the 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified, based upon the following votes: Director Nominee Votes For Votes Withheld Broker Non-Vote Robert Brainin 7,904,120 338,790 461,706 Ronnie
Latest Champions Oncology news
We have not published a story on Champions Oncology yet. When there is news, it will appear here.
What Champions Oncology does
Champions Oncology, Inc. is a technology-enabled research organization creating technology solutions for use in drug discovery and development. Its research center operates in regulatory and non-regulatory environments and includes computational and experimental research platforms. At the core is a proprietary bank of Patient Derived Xenograft (PDX) models, called TumorBank, which the company says currently includes approximately 1,500 PDX models reflecting late stage, pretreated and metastatic patients who enroll in clinical trials. These models are deployed into advanced in vivo and ex vivo pharmacology platforms. Its Datacenter combines the company's proprietary oncology dataset, which includes approximately 3,500 molecular datasets and approximately 3,000 clinical drug responses, with approximately 20,000 publicly available datasets. The text describes the TumorBank as living, so the company can keep characterizing it over time, and its platforms are designed to facilitate drug discovery and development at lower costs and increased speeds.
| Product or program | What it is | Stage |
|---|---|---|
| TumorBank PDX models | Patient derived xenograft models used in in vivo and ex vivo pharmacology platforms | |
| Datacenter | Oncology dataset combining proprietary TumorBank data with public datasets |
Champions Oncology annual financials
| Line | FY ended Apr 30, 2026 | FY ended Apr 30, 2025 |
|---|---|---|
| Research and development | $9.1 million | $6.8 million |
| Net income (loss) | -$1.2 million | $4.7 million |
| Cash from operations | -$4.5 million | $7.4 million |
| Cash and equivalents | $4.9 million | $9.8 million |
Questions about Champions Oncology
What is the ticker symbol of Champions Oncology?
Champions Oncology, Inc. trades under the ticker CSBR on NASDAQ.
Where is Champions Oncology listed?
Champions Oncology, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:2I3.
What is the SEC CIK of Champions Oncology?
The SEC Central Index Key (CIK) for Champions Oncology, Inc. is 771856. Its filings are on SEC EDGAR.
How many shares does Champions Oncology have outstanding?
13,918,569 shares as of 2026-09-09, per the cover page of its 10-Q filed 2026-09-11.
Which country or territory is Champions Oncology listed under?
Our directory records Champions Oncology, Inc. under United States.
What does Champions Oncology do?
Our directory classifies Champions Oncology, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Champions Oncology?
The ISIN recorded for Champions Oncology, Inc. is US15870P3073.
Does aibio.space cover Champions Oncology?
aibio.space lists Champions Oncology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Champions Oncology incorporated?
SEC records list its state or country of incorporation as DE.
What does Champions Oncology develop?
Champions Oncology, Inc. is a technology-enabled research organization creating technology solutions for use in drug discovery and development. Its research center operates in regulatory and non-regulatory environments and includes computational and experimental research platforms.
What is TumorBank PDX models from Champions Oncology?
TumorBank PDX models: Patient derived xenograft models used in in vivo and ex vivo pharmacology platforms Stage: not stated.
What is Datacenter from Champions Oncology?
Datacenter: Oncology dataset combining proprietary TumorBank data with public datasets Stage: not stated.
Is Champions Oncology profitable?
Champions Oncology, Inc. reported a net loss of $1.2 million for the fiscal year ended Apr 30, 2026, and used $4.5 million of cash in operations, per its annual report to the SEC.
How much does Champions Oncology spend on research and development?
$9.1 million in the fiscal year ended Apr 30, 2026, per its annual report.
How much cash does Champions Oncology have?
$4.4 million in cash at Jul 31, 2026, per its 10-Q.
Investor discussion: Champions Oncology
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Stock chart
SEC filings and registration
- SEC name
- Champions Oncology, Inc.
- CIK
- 771856
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- CSBR (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- April 30
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 855 N. WOLFE STREET, BALTIMORE, MD, 21205
- Phone
- 410-369-0365
- Shares outstanding
- 13,918,569 as of 2026-09-09 (10-Q filed 2026-09-11)
- Former names
- CHAMPIONS BIOTECHNOLOGY, INC.; CHAMPIONS SPORTS INC
Recent filings
Listing details
- Company
- Champions Oncology, Inc.
- Ticker
- CSBR
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- US15870P3073
- Other listed symbols
- GETTEX:2I3
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction